Get the Stockscreener App
0.2333
3.62%
0.00815
Biorestorative Therapies Inc stock is traded at $0.2333, with a volume of 831.35K.
It is up +3.62% in the last 24 hours and down -18.16% over the past month.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
See More
Previous Close:
$0.2251
Open:
$0.233
24h Volume:
831.35K
Relative Volume:
0.09
Market Cap:
$5.94M
Revenue:
$359.70K
Net Income/Loss:
$-14.24M
P/E Ratio:
-0.1424
EPS:
-1.6376
Net Cash Flow:
$-10.91M
1W Performance:
+1.46%
1M Performance:
-18.16%
6M Performance:
-84.85%
1Y Performance:
-86.90%
1-Day Range:
$0.2203
$0.236
1-Week Range:
$0.20
$0.236
52-Week Range:
$0.19
$2.045
Biorestorative Therapies Inc Stock (BRTX) Company Profile
Name
Biorestorative Therapies Inc
Sector
Industry
Phone
(631) 760-8100
Address
40 MARCUS DRIVE, MELVILLE
Compare BRTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRTX
Biorestorative Therapies Inc
|
0.2333 | 5.94M | 359.70K | -14.24M | -10.91M | -1.6376 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biorestorative Therapies Inc Stock (BRTX) Latest News
BioRestorative Therapies Boosts Executive Compensation and Equity Incentives - TipRanks
BioRestorative (NASDAQ: BRTX) details 2025 executive pay and bonuses - Stock Titan
Biorestorative Therapies | EFFECT: Others - Moomoo
Biorestorative Therapies | 424B3: Prospectus - Moomoo
BioRestorative Therapies (NASDAQ: BRTX) registers 15.29M warrant shares - Stock Titan
BioRestorative to present clinical, preclinical data at ISCT - Investing.com UK
BioRestorative to present clinical, preclinical data at ISCT By Investing.com - Investing.com India
BioRestorative Therapies Presents New Data on MSC-Derived Programs at ISCT 2026 Annual Meeting - Quiver Quantitative
BioRestorative brings two programs to Dublin, including Phase 2 spine trial data - Stock Titan
Biorestorative Therapies, Inc. (BRTX) reports Q4 loss, lags revenue estimates - MSN
[EFFECT] BioRestorative Therapies, Inc. SEC Filing - Stock Titan
Here's why Biorestorative Therapies (BRTX) looks ripe for bottom fishing - MSN
Biorestorative Therapies | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingmoomoo - Moomoo
BioRestorative Therapies (NASDAQ: BRTX) files S-1/A amendment; counsel opinion added - Stock Titan
Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing - Yahoo! Finance Canada
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Beats Revenue Estimates - MSN
BioRestorative Therapies (BRTX) price target decreased by 15.79% to 8.16 - MSN
BioRestorative prices $5M stock offering - MSN
BioRestorative Therapies Updates Corporate Presentation for Investors - The Globe and Mail
BioRestorative Therapies : Investor Presentation - marketscreener.com
BioRestorative Therapies updates corporate presentation, posts materials on website - TradingView
Updated BioRestorative (NASDAQ: BRTX) investor deck for conferences - Stock Titan
BRTX (BioRestorative Therapies Inc.) posts narrower Q4 2025 loss than consensus estimates, shares rise 2.61 percent in today's trading.Subscription Growth - Cổng thông tin điện tử tỉnh Tây Ninh
BioRestorative partners with dermatologist for clinical study By Investing.com - Investing.com India
BRTX Financials: Income Statement, Balance Sheet & Cash Flow | Biorestorative Therapies Inc - Stock Titan
BioRestorative partners with dermatologist for clinical study - Investing.com
BioRestorative Therapies, Inc. (BRTX) announces a strategic partnership with Dr. David J. Goldberg, a leading global authority in the field of dermatology. - Bitget
BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform - marketscreener.com
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading 5.7% HigherHere's Why - MarketBeat
Huge share increase and Nasdaq bid warning for BioRestorative (BRTX) - Stock Titan
Movement Recap: Is BioRestorative Therapies Inc stock a hidden gemDividend Hike & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Analyst Upgrade: Is BioRestorative Therapies Inc still a buy after recent gainsInsider Selling & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Biorestorative Therapies | DEF 14A: Definitive information statements - Moomoo
BioRestorative partners with 203 Creates for skincare brand launch - Investing.com Australia
BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform - Sahm
BioRestorative Therapies, Inc. Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform - marketscreener.com
BioRestorative partners with 203 Creates for skincare brand launch By Investing.com - Investing.com Canada
BioRestorative Therapies Announces Strategic Collaboration with 203 Creates - National Today
Biorestorative Therapies Inc Stock (BRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):